Background. Protection against Haemophilus influenzae type b (Hib), a rapidly invading encapsulated bacteria, is dependent on maintenance of an adequate level of serum antibody through early childhood. In many countries, Hib vaccine booster doses have been implemented after infant immunization to sustain immunity. We investigated the long-term persistence of antibody and immunological memory in primary-school children following infant (with or without booster) Hib vaccination.
In the United Kingdom, Haemophilus influenzae type b (Hib) conjugate vaccine was introduced into the routine infant immunization schedule in 1992 (3 doses at 2, 3, and 4 months of age, without a booster). A concurrent catch-up campaign was undertaken at the time of vaccine introduction (a single dose offered to children between 6 months and 4 years of age) to provide rapid control of Hib disease. The initial decrease in the incidence of Hib disease in children aged <5 years of age in England and Wales was dramatic, from 22.9 per 100 000 in 1990 to 0.65 per 100 000 in 1998 [1] , with evidence of high direct vaccine effectiveness [2] . However by 2000, invasive Hib disease had resurged [3] , reaching 4.6 per 100 000 in 2002, and reports of vaccine failures began to increase [4] despite unchanging vaccine coverage [1] .
Multiple factors are likely to have contributed to the rise in Hib disease in the United Kingdom, including relatively low postimmunization antibody concentrations in infants [5] , declining effectiveness with time [1] , lower effectiveness in infants compared to older children vaccinated during the catch-up campaign [1] , decreased carriage rates and therefore decreased natural boosting [6] , waning of herd immunity [7] , use of lowerefficacy acellular pertussis (aP) (rather than whole-cell pertussis) combination vaccines [8] , and concomitant administration of serogroup C meningococcal (MenC) conjugate vaccine [9] .
A substantial additional factor in the United Kingdom was the lack of a fourth (booster) dose of Hib vaccine in the second year of life. Early surveillance results, before the resurgence in cases, indicated that despite waning Hib antibody concentrations with time, vaccine effectiveness remained high ( providing confidence in the protective efficacy of immunological memory), and therefore a booster dose was deemed unnecessary [5] . However, ongoing surveillance detected earlier and increased overall numbers of vaccine failures in progressive annual birth cohorts (before the widespread use of aP-Hib combination vaccine) [3] . Furthermore, only 44% of true vaccine failures were associated with clinical risk factors (eg, prematurity and immunoglobulin deficiency), suggesting that population immunity was not sufficient for protection [10] . In countries where a booster Hib dose was given in the second year of life, there was no increase in vaccine failures or Hib disease, and antibody concentrations were sustained up to 10 years of age (despite the use of aP-Hib combination vaccines) [11, 12] .
In 2003, to counteract the waning population immunity against Hib disease in the United Kingdom, a second catchup campaign was implemented (a single fourth booster Hib vaccine dose was offered to all children between 6 months and 4 years of age), with the aim of boosting Hib antibody concentrations and increasing herd immunity [13, 14] . In 2006, the UK Department of Health introduced Hib, MenC, and pneumococcal conjugate vaccine boosters in the second year of life to prevent further breakthrough cases and sustain control of disease caused by these encapsulated bacteria [15] .
There are no published data on the long-term persistence of Hib antibody following infant priming (without booster) in primary-school-aged children or immune responses (humoral or cellular) following a Hib vaccine booster dose in this age group. We measured the persistence of serum anti-polyribosylribitol phosphate (PRP) immunoglobulin G (IgG) concentration in 250 primary-school-aged children who had been immunized 6-12 years previously [16] . We also measured the circulating Hib-specific plasma and memory B cells. Following a Hib-MenC conjugate vaccination, given to all children, we measured the serum Hib IgG concentration and circulating frequency of Hib-specific B cells again after 1 week, 1 month, and 1 year. The relationship between circulating Hib-specific memory B-cell frequencies or antibody at baseline and B cells and antibody following the booster was investigated.
MATERIALS AND METHODS

Study Design and Participants
An open-label phase 4 study was undertaken in Oxfordshire, United Kingdom, from September 2006 to July 2008. Details of this study have been previously described [16] . In brief, participants were healthy 6-to 12-year-old children who had received all UK scheduled vaccinations, including 3 doses of Hib-, tetanus-, pertussis-, and diphtheria-containing vaccines before 7 months of age; a preschool tetanus, pertussis, and diphtheria booster (fourth dose); and a MenC conjugate vaccine during the 1999-2001 UK MenC mass immunization campaign. Some children also received a fourth dose of Hib vaccine during the 2003 catch-up campaign. Each participant's individual immunization history was verified from medical or centralized immunization records. Children were stratified into 7 age groups. Ethical approval was obtained from the Oxfordshire Research Ethics Committee (06/Q1605/100). The study was registered with www.controlled-trials.com (ISRCTN728588998).
Vaccine and Blood Sampling
At baseline (study enrollment), a maximum of 10 mL of blood was obtained. All participants subsequently received a single Hib-MenC conjugate vaccination (Menitorix, GlaxoSmithKline Vaccines). Additional blood samples were collected after 1 week in 75 participants and at 1 month and 1 year in all participants [16] .
Immunogenicity Measures
Antibody (IgG) concentrations for the Hib capsular polysaccharide, PRP, were determined using an indirect immunofluorescence multiplex assay (Luminex DTH) by the Public Health England Vaccine Evaluation Unit (Manchester), using a modified published method [17] .
The frequency of circulating antigen-specific antibody secreting cells were determined by the B-cell enzyme-linked immunospot (ELISpot) assay at the Oxford Vaccine Group, University of Oxford, United Kingdom. The ex vivo ELISpot method was used to detect the frequency of antigen-specific plasma cells that spontaneously secrete antibody. Preparation of ELISpot plates and method of detection of antigen-specific plasma (fresh) cells and memory B cells (cultured lymphocytes) have been previously described (for meningococcal C-specific antibody secreting cells) [18] . For the detection of Hib-specific plasma and memory cells, 96-well plates with a polyvinylidene difluoride membrane (Millipore) were coated with 2 µg/mL Hib polysaccharide conjugated to human serum albumin (National Institute of Biological Standards and Controls).
Statistical Analysis
The geometric mean concentration (GMC) of anti-PRP IgG and the proportion of children with an anti-PRP concentration ≥0.15 µg/mL ( putative correlate for short-term protection) [19] and ≥1.0 µg/mL ( putative correlate for long-term protection) [20] were calculated. Frequencies of antigen-specific plasma or memory B cells were expressed per million peripheral blood mononuclear cells (PBMCs). Geometric mean frequencies of plasma and memory B cells were calculated. All antibody concentrations and memory B-cell frequencies were log transformed for analysis. A value of 0.01 was added to all memory B-cell measures before transformation to avoid zero values being excluded after transformation. We explored the relationship between the Hib measures and age using analysis of variance, adjusting for baseline measures when necessary. Comparison of protection rates was carried out using χ 2 test. The correlations between memory cells at baseline and memory cells and antibody were assessed using Spearman rank correlation, adjusting for age at baseline. All data were analyzed using Excel 2007 software (Microsoft Office), Stata software (version 10, StataCorp), and SAS software (version 9.1).
RESULTS
Demographic characteristics of the participants have been previously published [16] . In brief, of 250 enrolled participants, 249 received the Hib-MenC booster, 244 (98%) were included in the analysis, and 230 (92%) completed all study visits [16] . The median age of enrollment was 8.6 years (range, 6.4-12.6 years) ( Table 1) . Participants in each group were of similar age on receipt of their third Hib dose (0.35-0.52 years of age). Time since the third Hib dose increased sequentially across the groups (6.7-12.7 years). A summary of antibody and B-cell data is provided in Tables 2 and 3 , respectively. Overall at baseline (enrollment), 78% (191/244) and 55% (134/244) of participants had anti-PRP concentrations above the short-term (≥0.15 µg/mL) and long-term (≥1.0 µg/mL) correlates of protection, respectively. Younger children had higher anti-PRP concentrations; were more likely to have anti-PRP concentrations above the putative correlates of protection and higher frequencies of Hib memory cells than older children (P value test for trend ≤.001 for all measures) (Tables 2  and 3 ). However, at baseline overall, circulating Hib-specific memory B cells were found infrequently in all age groups.
Seven days after the Hib-MenC booster was administered, a very high frequency of circulating Hib-specific plasma cells (264-643 per million PBMCs) ( Table 3 ) and memory B cells (32-97 per million cultured PBMCs) (Table 3) were detected. One month after the Hib-MenC booster, higher serum anti-PRP concentrations (Table 2 ) and memory B-cell frequencies (Table 3) were found in younger children (P value test for trend = .0001 for both), and all but 1 participant (99.6%) had an anti-PRP concentration considered to be protective (Table 2) .
One year after the Hib-MenC booster, serum anti-PRP concentrations and circulating Hib-specific memory B-cell Participants were stratified into 7 groups (age bands were determined on the basis of age at receipt of and number of MenC conjugate vaccine doses in the parent study) [16] . All participants received 3 priming doses of Hib vaccine at <7 months of age. Some children received a fourth Hib vaccine during the 2003 UK catch-up campaign (proportion in each group is shown).
Abbreviations: Hib, Haemophilus influenzae type b; MenC, meningococcal C. Participants were stratified into 7 groups (age bands were determined on the basis of age at receipt of and number of MenC conjugate vaccine doses in the parent study) [16] . All participants received 3 priming doses of Hib vaccine at <7 months of age. Some children received a fourth Hib vaccine during the 2003 UK catch-up campaign (proportion in each group is shown). Baseline refers to blood sample collected at enrollment, prior to a Hib-MenC booster. The rows 1 month and 1 year refer to time since Hib-MenC booster.
Abbreviations: CI, confidence interval; GMC, geometric mean concentration; Hib, Haemophilus influenzae type b; IgG, immunoglobulin G; MenC, meningococcal C; PRP, polyribosylribitol phosphate. a Analysis of variance trend test. Values are expressed as No., followed by GMF (95% CI), unless otherwise indicated. Participants were stratified into 7 groups (age bands were determined on the basis of age at receipt of and number of MenC conjugate vaccine doses in the parent study) [16] . All participants received 3 priming doses of Hib vaccine at <7 months of age. Some children received a fourth Hib vaccine during the 2003 UK catch-up campaign (proportion in each group is shown). Baseline refers to blood sample collected at enrollment, prior to a Hib-MenC booster. The rows 1 week, 1 month, and 1 year refer to time since Hib-MenC booster.
Abbreviations: CI, confidence interval; GMF, geometric mean frequency; Hib, Haemophilus influenzae type b; MenC, meningococcal C; N/A, not applicable. a Analysis of variance trend test.
frequencies had declined from the 1-month postbooster levels but remained significantly higher than at baseline (Tables 2  and 3 ). Persistent putative short-and long-term protective anti-PRP concentrations were found in 99.6% and 96% of participants, respectively. There was suggestion of a trend for higher frequencies in younger participants (P value test for trend = .07; Table 3 ).
There was no correlation between the frequency of Hibspecific memory B cells at baseline and antibody or B cells at any time point (Table 4) . A strong evidence of positive correlation was found between Hib antibody concentrations at baseline and at 1 year following the Hib-MenC booster (n = 225, r = 0.47, P < .0001). Significant negative correlations were found between baseline antibody and memory B cells at 1 week and baseline antibody and plasma cells at 1 week postbooster.
Not all children received a fourth Hib booster dose prior to this study (Table 1) . Overall, 32% (78/244) of enrolled children had received a fourth Hib dose at mean age of 3.9 years (range, 3.6-4.6). Almost 70% of younger participants received a fourth Hib dose (median age, 7.0-8.0 years) compared with <20% of older participants (median age, 8.3-12.1 years). In all age groups, at baseline and at all postbooster time points, higher anti-PRP GMCs and a higher median number of Hib memory B cells were found in participants who had received a fourth Hib dose (Tables 5 and 6 ). Overall at baseline, anti-PRP GMCs were 3.11 µg/mL (95% confidence interval [CI], 2.25-4.29) in those who had received a fourth Hib dose compared with 0.71 µg/mL (95% CI, .49-1.02) in those who did not receive a fourth Hib dose. Furthermore, a greater proportion of participants who had received a fourth Hib dose, vs no receipt, had anti-PRP concentrations above the putative short-and long-term correlates of protection: 95% (74/78) vs 70% (117/166), and 79% (62/ 78) vs 43% (72/166), respectively ( Figure 1A and 1B) .
DISCUSSION
Persistence of Hib Immunity in Childhood
This is the first study to report on the long-term (>6 years) persistence of Hib antibody concentrations in children who had Data are expressed as (No.) PRP IgG GMC, µg/mL, unless otherwise indicated. Participants were stratified into 7 groups (age bands were determined on the basis of age at receipt of and number of meningococcal C conjugate vaccine doses in the parent study) [16] . All participants received 3 priming doses of Hib vaccine at <7 months of age (n = 244). Some children received a fourth Hib vaccine during the 2003 UK catch-up campaign (n = 78).
Abbreviations: CI, confidence interval; GMC, geometric mean concentration; Hib, Haemophilus influenzae type b; IgG, immunoglobulin G; PRP, polyribosylribitol phosphate.
received a 3-dose infant priming schedule without a booster. We found that sustained vaccine-induced Hib immunity is dependent on time since infant priming: Younger children (aged 6-7 years), primed more recently, had better persistence of anti-PRP IgG than older children (aged 8-11 years). Moreover, we found that sustained vaccine-induced Hib immunity is dependent on receipt of a Hib booster (fourth dose). Overall, in children aged 6-12 years, substantially higher anti-PRP IgG GMCs and anti-PRP ≥1.0 µg/mL were found in those who had compared with those who had not received a fourth Hib dose (3.11 µg/mL and 79% vs 0.71 µg/mL and 43%, respectively). Overall, in our cohort that had not received a fourth Hib dose, baseline anti-PRP IgG GMCs were high, relative to other studies. In the youngest group (6.7 years since third Hib dose), the anti-PRP IgG GMC was 1.7 µg/mL, much higher than levels found in previous short-term persistence studies (1-4 years since third Hib dose) of 0.21-0.89 µg/mL (Supplementary Table 1 ) [21] [22] [23] [24] [25] [26] [27] . This suggests there may have been ongoing natural boosting via exposure to PRP or cross-reacting antigens in our cohort. Indeed, a Hib carriage study undertaken in healthy fully immunized UK schoolchildren in 2005 found a carriage rate of 4.2% in 6-to 16-year-old children, none of whom had received a Hib vaccine booster [6] . Other studies have reported on the age of acquisition of natural immunity to Hib through nasopharyngeal carriage [28, 29] and the development of immunity to Hib from species such as Escherichia coli that are cross-reactive with PRP [30, 31] .
Previously published data have shown that receipt of a fourth Hib dose leads to a more sustained persistence of antibody and that this effect is greatest when given after the first year of life [23] . Data from studies on the persistence of Hib antibody following a priming plus booster schedule are shown in Supplementary Table 2 . In our study, anti-PRP IgG concentrations were very high in participants who had received a fourth Hib dose (3.1 µg/mL at 6-11 years after priming), similar to those in Finnish children who received a fourth Hib dose between 12 and 18 months of age (3.4 µg/mL at 10 years after priming), where ongoing boosting of Hib responses through natural antigenic exposure has also been suggested [12] .
Better persistence of anti-PRP IgG concentrations are found after Hib priming with concomitant MenC tetanus toxoid conjugate than MenC CRM (C-reactive material conjugate) [9, 21, [32] [33] [34] [35] . In our study, 93% (227/244) of participants were primed with MenC CRM and only the youngest group received concomitant MenC (all older children received subsequent MenC vaccine during the 1999-2000 UK MenC catch-up campaign); therefore, this interaction could not be assessed.
Frequency of Hib-Specific Memory B Cells at Steady State
Circulating Hib-specific memory B cells were rarely found at baseline in this primary-school cohort (as we have previously described for MenC) [18] . However, their presence was related to time since priming (higher frequencies in younger children) and receipt of a fourth Hib dose. The median frequency of Hibspecific memory B cells was 0.001% of total IgG memory B cells (regardless of receipt of a fourth Hib dose), even lower than the median frequency of MenC-specific memory B cells (0.005%) [18] , and lower than a previous study on MenC-specific memory B cells in toddlers (0.02%) [36] . In this study, the Hib vaccine antigen encounter for children who did not receive a fourth Hib dose was 6.7-11.7 years (mean, 8.7 years), longer than for MenC (mean 6.8 years). These findings suggest that recirculating memory B cells decline with time. This may be due to either a loss of cells or sequestration in bone marrow. There was no correlation between the frequency of Hib-specific memory B cells and anti-PRP IgG concentration at baseline. This may indicate that most antigen-specific memory B cells reside in the peripheral lymphoid tissue at steady state [37, 38] , and therefore Figure 1 . Proportion of participants with serum polyribosylribitol phosphate (PRP) immunoglobulin G (IgG) ≥0.15 µg/mL (A) and serum PRP IgG ≥1.0 µg/ mL (B) at baseline, by receipt of fourth Haemophilus influenzae type b (Hib) dose and age at baseline. Participants were stratified into 7 groups (age bands were determined on the basis of age at receipt of and number of meningococcal C conjugate vaccine doses in the parent study) [16] . All participants received 3 priming doses of Hib vaccine at <7 months of age (n = 244). Some children received a fourth Hib vaccine during the 2003 UK catch-up campaign (n = 78).
the circulating frequency may not accurately reflect the total number available to be activated on subsequent antigenic exposure.
Immunological Memory to Hib Conjugate Vaccine in Childhood
This was also the first study to assess the B-cell response following a booster Hib vaccine in primary-school-aged children. Overall, this study showed that Hib-specific plasma cell and memory B-cell frequencies at 7 days and 1 month after booster in primary-school children depend on time since priming and previous receipt of a booster (higher in younger children and in those who had received a fourth Hib dose). Children in this study who had received a fourth Hib dose had done so at a similar age (mean 3.9 years), and so the difference between their Hib vaccine antigen exposure is time since, rather than age at, fourth Hib booster. Younger children (median age, 7.0 years) had been primed and boosted more recently (6.7 and 3.5 years prior) than older children (median age, 12.1 years, primed and boosted 11.7 and 7.7 years prior, respectively). These data suggest that frequent vaccine antigen exposure may not only be important for persistence of immediately available circulating antibody ( presumably via production of longlived plasma cells in the bone marrow) but also for maintaining an adequate memory B-cell pool in the peripheral lymphoid tissues (for differentiation and proliferation into plasma cells to produce "mop-up" antibody on antigen reencounter). We hypothesize that the majority of these antigen-specific plasma cells are derived from preexisting memory B cells (hence higher frequencies enumerated in children who had vaccine antigen more recently). Further research in this area will determine the proportion of these antigen-specific plasma cells that are newly generated from naive B cells and the proportion that are derived from recirculating memory B cells.
Following a Hib-MenC booster, immunological memory was evident in all study children. Overall, anti-PRP IgG concentrations increased >6-fold from steady state to 1 month post booster. Antibody (IgG) fold rises were dependent on steady-state concentrations (higher fold rise in those with lower steadystate IgG concentrations). Children who had received a fourth Hib dose had evidence of a greater Hib-specific memory pool (higher anti-PRP GMC at 1 month and sustained to 1 year following Hib-MenC booster) than in children who had not received a fourth dose. Furthermore, there was evidence of negative feedback (significant negative correlation between anti-PRP IgG at baseline and plasma cells and memory B cells at 7 days following booster). This suggests that preexisting antigen-specific memory B cells may not proliferate and differentiate into antigen-specific plasma cells or that newly derived plasma cells are not generated from naive B cells, above a certain steady-state serum antibody threshold. Negative feedback limiting antibody responses has been observed in other studies. For example, a third dose of MenC vaccine in infants did not induce a higher antibody concentration compared with the second dose [39] , higher prebooster MenC concentrations attenuated antibody responses in 1-year-old children [36] , and higher prebooster tetanus concentrations attenuated antibody responses in adults [40] . These observations are thought to be the result of competition between the high concentrations of preexisting antibody and the membrane-bound B-cell receptors for the vaccine antigen, thereby impairing the activation of B cells [41] .
CONCLUSIONS
This study showed that sustained vaccine-induced immunity from Hib conjugate vaccine in young children is dependent on time since infant priming and receipt of a booster. Baseline anti-PRP IgG concentrations in this study were higher than those found in short-term persistence studies, suggesting the possibility of ongoing natural boosting of Hib immunity in UK school-aged children through carriage. Natural boosting may be an important mechanism for the maintenance of individual and population immunity.
Ongoing surveillance reports following the introduction of a fourth Hib dose in the second year of life in the United Kingdom in 2006, reveal that the number of cases of invasive Hib disease is at an all-time low, from 864 in 1990 (86% [745/ 864] in children <5 years of age) down to only 30 in 2010 (20% [6/30] in children <5 years of age) [42] . Many Western countries now include a Hib vaccine in the second year of life to optimize protection over the high-risk period (<5 years of age). However many resource-limited countries still do not have routine Hib vaccine in their infant immunization schedule, and other countries that have started an infant Hib priming schedule cannot afford a booster. The data presented in this study indicate that booster doses play an important role in maintaining serum antibody concentrations and supporting expansion of memory B-cell clones, and should therefore be considered in all routine Hib immunization schedules.
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